



I. Epidemiological profile

Population	2013	%
High transmission (> 1 case per 1000 population)	7 060 000	7
Low transmission (0-1 cases per 1000 population)	71 400 000	73
Malaria-free (0 cases)	19 900 000	20
Total	98 360 000	

Parasites and vectors

Major plasmodium species: *P. falciparum* (79%), *P. vivax* (20%)
 Major anopheles species: *An. flavirostris*, *An. maculatus*, *An. balabacensis*, *An. litoralis*

Programme phase: Control

Reported confirmed cases: 6514
 Reported deaths: 12

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2006
	ITNs/LLINs distributed to all age groups	Yes	2000
IRS	IRS is recommended	Yes	2002
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2004
	Malaria diagnosis is free of charge in the public sector	Yes	2003
Treatment	ACT is free for all ages in public sector	Yes	2003
	Artemisinin-based monotherapies withdrawn	Yes	2003
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2006
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2007
	G6PD test is a requirement before treatment with primaquine	Yes	2011
	Directly observed treatment with primaquine is undertaken	Yes	2010
	System for monitoring of adverse reactions to antimalarials exists	Yes	2009



Intervention	Policies/strategies	Yes/No	Year adopted
Surveillance	ACD for case investigation (reactive)	Yes	2009
	ACD of febrile cases at community level (pro-active)	No	-
	Mass screening is undertaken	Yes	2009
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AL	2009
First-line treatment of <i>P. falciparum</i>	AL+PQ	2009
Treatment failure of <i>P. falciparum</i>	QN+CL; QN+D; QN+T	2002
Treatment of severe malaria	QN+T	2002
Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2002
Dosage of primaquine for radical treatment of <i>P. vivax</i>	0.50 mg/kg (14 days)	
Type of RDT used	<i>Pf</i> + <i>Pv</i> specific (Combo)	



Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
CQ	2005-2010	0	0	0	28 days	2	<i>P. vivax</i>



III. Financing




IV. Coverage




V. Impact



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths



Impact: Achieved >75% decrease in case incidence in 2013